image dons

I make a donation


Evaluation of the antiplatelet effect of intravenous clopidogrel (MDCO-157) versus oral clopidogrel


La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

21e Colloquium (14 mars 2023)
Inscrivez-vous dès maintenant !

logo étude


A phase I, randomized, open-label, crossover study to evaluate the antiplatelet effect of intravenous clopidogrel (MDCO-157) versus oral clopidogrel

date de réalisation


nombre de patients


nombre de centres participants

Monocentrique (Pitié-Salpêtrière)

type de financement

Privé (The Medicines Company)



Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Open-label, Randomized, Cross-over Evaluation (AMPHORE)

Study Description

Following a first, dose ascending study that enrolled 144 normal healthy volunteers (NHVs), this study, to be conducted in approximately 36 NHVs, will provide pertinent information in determining the dose-response of MDCO-157 for platelet aggregation inhibition and P2Y12 receptor inhibition effects and in selection of doses that match the antiplatelet effects of 300 mg PLAVIX® ®. The study will also provide additional data for pharmacokinetics (PK), safety and tolerability of single doses of MDCO-157.



  • Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel : The Randomized Cross-Over AMPHORE Study
    Jean-Philippe Collet, Christian Funck-Brentano, Jayne Prats, Joe-Elie Salem, Jean-Sébastien Hulot, Edith Guilloux, Ming-yi Hu, Kan He, Johanne Silvain Vanessa Gallois, Delphine Brugier, Ghalia Anzaha, Sophie Galier, Nathalie Nicolas, Gilles Montalescot
    Publicated in American Journal of Cardiovascular Drugs

Autres études



En cours

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.


En cours

Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.


En cours

Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients